Successful test in breast cancer patients: the active agent digoxin, a cardiac medication, dissolves clusters of circulating breast cancer cells in the blood, thus reducing the risk of metastases ...

Virginia G. Kaklamani, MD, DSc, discusses datopotamab deruxtecan and other antibody-drug conjugates available for patients with unresectable or metastatic hormone receptor-positive, HER2-negative ...

Certain tumor types do not remain at their point of origin but spread throughout the body and form metastases. This is ...

The Under-oil Open Microfluidic System enhances tumor cell-ECM interaction studies, improving anti-metastatic drug testing ...

LONDON - ANGLE plc, a leading liquid biopsy company, has announced a significant development in cancer treatment strategy, ...

Two U.S. companies teamed up to treat cancer patients using an unproven blood filter in Antigua, out of reach of American ...

Both Harvard University and Johns Hopkins University sites were recently added as participating sites in FLAMINGO-01 in the US and both principal investigators, Dr. Laura Spring and Dr. Cesar ...

The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the body or cannot be surgically removed.

Findings showed datopotamab deruxtecan reduced the risk of disease progression or death by 37% compared with chemotherapy.

Individuals with advanced breast cancer at diagnosis are more likely to have prevalent cardiovascular disease.